| Description | AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1]. |
| In vitro | AZD0284 (0.37 μM; 5 days) inhibits IL-17A production in human TH17 cells[1]. AZD0284 reduces polarization of TH17 into pathogenic TH17/1 cells. AZD0284 decreases frequency of single IL-17+cell as well as double positive TH17/1 cells. AZD0284 reduces IL-17A secretion and RNA expression of IL-17A, IL-17F, IL-22 and IL-23R[1][2]. |
| Target activity | RORγ:7.4(pIC50) |
| molecular weight | 524.43 |
| Molecular formula | C21H18F6N2O5S |
| CAS | 2101291-07-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 99 mg/mL (188.77 mM), Sonication is recommended. |
| References | 1. Narjes, F, et al. The discovery of AZD0284, an inverse agonist of the nuclear receptor RORg. American Chemical Society, 2017 Drug Design and Delivery Symposium 26 October 2017 |